iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
Plus, news about AnaptysBio, Alzamend, AEON Biopharma and argenx: iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital Management and Boxer Capital — …